AMGEN INC (1AMGN.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1AMGN - US0311621009 - Common Stock
1AMGN.MI Key Statistics, Chart & Performance
The current stock price of 1AMGN.MI is 277.8 EUR. In the past month the price decreased by -10.05%.
1AMGN.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1AMGN.MI.
1AMGN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1AMGN.MI. 1AMGN.MI scores excellent on profitability, but there are concerns on its financial health.
1AMGN.MI Financial Highlights
Over the last trailing twelve months 1AMGN.MI reported a non-GAAP Earnings per Share(EPS) of 18.67. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.47% | ||
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| Debt/Equity | 5.45 |
1AMGN.MI Forecast & Estimates
41 analysts have analysed 1AMGN.MI and the average price target is 289.78 EUR. This implies a price increase of 4.31% is expected in the next year compared to the current price of 277.8.
For the next year, analysts expect an EPS growth of 9.43% and a revenue growth 9.42% for 1AMGN.MI
1AMGN.MI Ownership
1AMGN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 64.78 | 42.56B | ||
| ARGX.BR | ARGENX SE | 64.74 | 42.53B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.42B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.92B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.92B | ||
| IVA.PA | INVENTIVA SA | N/A | 966.55M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 879.45M | ||
| 6IV.DE | INVENTIVA SA | N/A | 962.73M | ||
| PHIL.MI | PHILOGEN SPA | 18.95 | 631.58M |
Related stock screener links
About 1AMGN.MI
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA US
Employees: 28000
Phone: 18054471000
AMGEN INC / 1AMGN.MI FAQ
What does AMGEN INC do?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
What is the stock price of AMGEN INC today?
The current stock price of 1AMGN.MI is 277.8 EUR. The price decreased by -5.8% in the last trading session.
Does AMGEN INC pay dividends?
AMGEN INC (1AMGN.MI) has a dividend yield of 3.11%. The yearly dividend amount is currently 7.7.
How is the ChartMill rating for AMGEN INC?
1AMGN.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is AMGEN INC worth?
AMGEN INC (1AMGN.MI) has a market capitalization of 149.59B EUR. This makes 1AMGN.MI a Large Cap stock.
Who owns AMGEN INC?
You can find the ownership structure of AMGEN INC (1AMGN.MI) on the Ownership tab.